ATE304847T1 - Verwendung von cumarin oder seines hydroxy- derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem - Google Patents

Verwendung von cumarin oder seines hydroxy- derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem

Info

Publication number
ATE304847T1
ATE304847T1 AT01274892T AT01274892T ATE304847T1 AT E304847 T1 ATE304847 T1 AT E304847T1 AT 01274892 T AT01274892 T AT 01274892T AT 01274892 T AT01274892 T AT 01274892T AT E304847 T1 ATE304847 T1 AT E304847T1
Authority
AT
Austria
Prior art keywords
treatment
hydroxy derivative
lymphedema
cumarin
moderate
Prior art date
Application number
AT01274892T
Other languages
English (en)
Inventor
Massimo Chimenti
Andrea Fratter
Original Assignee
Mac Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mac Pharma S A S filed Critical Mac Pharma S A S
Application granted granted Critical
Publication of ATE304847T1 publication Critical patent/ATE304847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01274892T 2001-12-04 2001-12-04 Verwendung von cumarin oder seines hydroxy- derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem ATE304847T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2001/000613 WO2003047566A1 (en) 2001-12-04 2001-12-04 Use of coumarin or its hydroxy derivative for the treatment of medium or severe vascular and/or lymphatic edema

Publications (1)

Publication Number Publication Date
ATE304847T1 true ATE304847T1 (de) 2005-10-15

Family

ID=11133762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274892T ATE304847T1 (de) 2001-12-04 2001-12-04 Verwendung von cumarin oder seines hydroxy- derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem

Country Status (6)

Country Link
EP (1) EP1450788B8 (de)
AT (1) ATE304847T1 (de)
AU (1) AU2002217430A1 (de)
DE (1) DE60113569T2 (de)
ES (1) ES2249391T3 (de)
WO (1) WO2003047566A1 (de)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096887A (en) * 1984-03-01 1992-03-17 Lamorna Investments Proprietary Limited Treatment of high protein oedemas
GB2168696B (en) * 1984-12-21 1989-01-11 Boehringer Biochemia Srl Fluoro coumarins as antilymphoedema agents
US4616033A (en) * 1985-03-14 1986-10-07 Lamorna Investments Proprietary Ltd. 7 hydroxy-coumarin as a treatment for high protein oedemas
DE3715990C2 (de) * 1987-05-13 1993-10-28 Schaper & Bruemmer Gmbh Verwendung von Cumarin und 7-Hydroxy-cumarin
ATE200979T1 (de) * 1994-02-18 2001-05-15 Drossapharm Ag Transdermales therapeutisches system
GB9722600D0 (en) * 1997-10-24 1997-12-24 Bio Monde Holdings Internation Pharmaceutical compositon

Also Published As

Publication number Publication date
AU2002217430A1 (en) 2003-06-17
EP1450788B8 (de) 2006-05-03
ES2249391T3 (es) 2006-04-01
EP1450788B1 (de) 2005-09-21
DE60113569T2 (de) 2006-05-04
EP1450788A1 (de) 2004-09-01
DE60113569D1 (de) 2006-02-02
WO2003047566A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
CY1118206T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
FI972793A (fi) Nebivololin käyttö antiaterogeenisenä aineena
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
HUP0401501A2 (hu) Érrendszeri gyulladás kezelése vagy megelőzése szterin-felszívódást gátló anyagokat tartalmazó gyógyszerkészítmények alkalmazásával
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
HUP0401913A2 (hu) Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény
ATE304847T1 (de) Verwendung von cumarin oder seines hydroxy- derivats zur behandlung von mittelschwerem oder schwerem gefäss- und/oder lymphödem
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69904465D1 (de) Therapie von depressionen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE386513T1 (de) Verwendung von angelicin und seiner strukturellen analoga zur behandlung von thalassämie
DE60328022D1 (de) Neue verwendung von rapamycin und strukturellen analoga hiervon
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
ATE311197T1 (de) Heilmittel und/oder vorbeugungsmittel gegen fettleibigkeit
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1450788

Country of ref document: EP